human milk oligosaccharide

Human milk oligosaccharides (HMOs) are a structurally diverse family of complex carbohydrates. Their identity determines molecular properties, analytical specifications, scientific evidence, and permitted conditions of use. Explore the available Sgnutri product, compare the information needed for formulation, and request documents for your target market.

What a human milk oligosaccharide is

HMOs share a lactose unit at the reducing end, but extensions and the addition of fucose or sialic acid create many distinct molecules. More than 200 HMO structures have been described in human milk. “HMO” therefore identifies a family; it does not provide a complete chemical identity for purchasing or formulation.

Structural groupRepresentative examplesWhy the distinction matters
Neutral fucosylated HMOs2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL)The position and linkage of fucose distinguish individual molecules and their analytical profiles.
Neutral non-fucosylated HMOsLacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT)LNT and LNnT have different linkages, so one cannot substitute for the other on name alone.
Acidic, sialylated HMOs3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL)Sialic acid gives these HMOs acidic character; linkage position again defines the specific ingredient.

A commercial specification should name the exact HMO or defined mixture. That identity determines the formula, molecular weight, CAS information where applicable, assay method, impurity profile, and regulatory review.

Structure determines functional relevance

HMO research describes several complementary biological pathways, and each depends on molecular structure. Some HMOs are selectively used by particular gut microorganisms, including certain Bifidobacterium strains. This selective use can influence microbial ecology and the metabolites produced during fermentation.

Some HMO structures can also interact with microbial adhesion targets as soluble decoys. The relevant binding behavior depends on the terminal sugars and linkages present, so evidence for one HMO cannot be transferred automatically to another.

Research also examines interactions between HMOs, intestinal epithelial processes, and immune signaling. Evidence remains structure-specific: a result associated with one molecule, dose, or population does not establish the same result for the entire HMO family.

Explore Sgnutri's HMO ingredient

White human milk oligosaccharide powder in a brown bowl on a white background.

Human milk oligosaccharides (HMOs)

A white to off-white powder or crystalline ingredient listing for buyers evaluating HMOs. Because HMOs are a group of structurally distinct compounds, the exact identity and product-specific specification should be confirmed with the quotation.

  • Formula chimicaVaries by HMO structure
  • Numero CASNo single CAS number applies to the HMO group
  • Peso molecolareVaries by oligosaccharide
  • AspettoPolvere o forma cristallina di colore da bianco a biancastro
  • Thermal behaviorSi decompone prima della fusione

2'-FL/HMO specification, quality, and handling

The reference specification supplied for 2'-fucosyllactose (2'-FL/HMO) lists the following composition and quality limits. These values describe the supplied 2'-FL/HMO specification; they are not a universal specification for every HMO structure.

Composition and physical criteria

TestReference specification
AspettoPolvere bianca
2'-FL≥94.0% w/w
Umidità≤9.0% w/w
D-lactose≤3.0% w/w
Difucosyl lactose≤2.0% w/w
Proteine≤100 mg/kg
Cenere≤0.5% w/w

Contaminant and microbiological criteria

TestReference specification
Endotoxin≤10 EU/mg
Arsenico (As)≤0.2 mg/kg
Piombo (Pb)≤0.05 mg/kg
Conteggio totale delle piastre≤500 CFU/g
Coliformi<10 CFU/g
SalmonellaNegative in 25 g

This 2'-FL/HMO is packed in 20 kg (44.1 lb) food-grade aluminum-foil composite bags. Its stated shelf life is 24 months under dry, clean, and ventilated storage conditions. Keep the bag closed and protect the powder from moisture during warehousing and sampling.

The current technical data sheet and batch certificate of analysis provide the applicable release criteria and results for an order.

Request the Current Specification

Choose an HMO by structure, evidence, and end use

The intended function narrows the relevant evidence, but the molecule named in that evidence still controls the ingredient choice. A study on 2'-FL, for example, does not establish an equivalent outcome for LNnT or a sialylated HMO. Consumer group, serving level, and final product format further determine whether that evidence fits a formulation.

Commercial ingredients with the same HMO name are not automatically interchangeable. Manufacturing process, purity, related sugars, microbiological limits, and stability can affect regulatory support, processing behavior, analytical release, and label review. A substitute should therefore be assessed against the finished-product specification and substantiation, not only the name on a catalog page.

In the United States, safety and regulatory support is tied to the specific substance, manufacturing description, specifications, food categories, use levels, and population described in the supporting record. Infant formula, foods for young children, dietary supplements, and general foods do not share one universal use framework. The FDA's GRAS Notice Inventory is a useful starting point for reviewing these conditions; a notice concerning another source or process does not automatically cover a quoted ingredient.

Ask Sgnutri to match the offered HMO and its technical documentation to the final product, consumer group, target use level, and market before a formulation is locked.

Discuss Your U.S. Application

Frequently asked questions

Is the ingredient sourced from human milk?

The manufacturing source is not stated in the general product information. Sgnutri can provide the source and process information for the specific product offered.

Can one HMO replace another at the same use level?

Not by default. Linkage pattern, purity, related sugars, stability, supporting evidence, and permitted conditions of use can differ. A valid substitution must satisfy the finished-product specification, use level, evidence, and target-market requirements.

Request Human Milk Oligosaccharide Information

Tell Sgnutri about your application and requested quantity to discuss an appropriate HMO product, sample availability, and commercial terms.

  • Telefono: +86-531-69959201
  • E-mail: [email protected]
  • WhatsApp: +86-186-53457231
  • Indirizzo: n. 4567, via Xinluo, distretto di Lixia, città di Jinan, provincia dello Shandong. Repubblica Popolare Cinese

Fields marked as required must be completed.